Thomas Nyström (T Nyström, David Nathanson)

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 19

Top Topics

Insulin Resistance

Heart Rate Variability

Community Dwelling

Silver Nanoparticles

Top Venues

Diabetes, obesity & metabolism

Journal of diabetes science and technology

This page only lists publications with an associated author ORCID identifier.

Publications

Thomas Nyström
Key results from observational studies and real-world evidence of sodium-glucose cotransporter-2 inhibitor effectiveness and safety in reducing cardio-renal risk. Diabetes, obesity & metabolism (2024)
Thomas Nyström, Mikael Andersson Franko, Johnny Ludvigsson, Marcus Lind, Martina Persson
Overweight or obesity, weight variability and the risk of retinopathy in type 1 diabetes. Diabetes, obesity & metabolism (2024)
Sofia Sterner Isaksson, Henrik Imberg, Irl B Hirsch, Erik Schwarcz, Jarl Hellman, Magnus Olof Wijkman, Jan Bolinder, Thomas Nyström, Helene Holmer, Sara Hallström, Arndís Finna Ólafsdóttir, Sofia Pekkari, William Polonsky, Marcus Lind
Discordance between mean glucose and time in range in relation to HbA 1c in individuals with type 1 diabetes: results from the GOLD and SILVER trials. Diabetologia 67 (8) (2024)
Vladimer Darsalia, Ellen Vercalsteren, Dimitra Karampatsi, Mihaela Oana Romanitan, Michael V Mazya, Thomas Nyström, Cesare Patrone
The need for registry-based studies in diabetes and stroke: A unique opportunity to understand whether diabetic treatments improve post-stroke outcome. Diabetes, obesity & metabolism (2024)
Sofia Sterner Isaksson, Henrik Imberg, Irl B Hirsch, Erik Schwarcz, Jarl Hellman, Magnus Olof Wijkman, Jan Bolinder, Thomas Nyström, Helene Holmer, Sara Hallström, Arndís Finna Ólafsdóttir, Sofia Pekkari, William Polonsky, Marcus Lind
Discordance between mean glucose and time in range in relation to HbA 1c in individuals with type 1 diabetes: results from the GOLD and SILVER trials. Diabetologia 67 (8) (2024)
Sofia Sterner Isaksson, Henrik Imberg, Irl B Hirsch, Erik Schwarcz, Jarl Hellman, Magnus Olof Wijkman, Jan Bolinder, Thomas Nyström, Helene Holmer, Sara Hallström, Arndís Finna Ólafsdóttir, Sofia Pekkari, William Polonsky, Marcus Lind
Discordance between mean glucose and time in range in relation to HbA 1c in individuals with type 1 diabetes: results from the GOLD and SILVER trials. Diabetologia 67 (8) (2024)
Thomas Nyström, Mikael Andersson Franko, Johnny Ludvigsson, Marcus Lind, Martina Persson
Overweight or obesity, weight variability and the risk of retinopathy in type 1 diabetes. Diabetes, obesity & metabolism 26 (6) (2024)
Vladimer Darsalia, Ellen Vercalsteren, Dimitra Karampatsi, Mihaela Oana Romanitan, Michael V Mazya, Thomas Nyström, Cesare Patrone
The need for registry-based studies in diabetes and stroke: A unique opportunity to understand whether diabetic treatments improve post-stroke outcome. Diabetes, obesity & metabolism 26 (7) (2024)
Sofia Sterner Isaksson, Henrik Imberg, Irl B Hirsch, Erik Schwarcz, Jarl Hellman, Magnus Olof Wijkman, Jan Bolinder, Thomas Nyström, Helene Holmer, Sara Hallström, Arndís Finna Ólafsdóttir, Sofia Pekkari, William Polonsky, Marcus Lind
Discordance between mean glucose and time in range in relation to HbA 1c in individuals with type 1 diabetes: results from the GOLD and SILVER trials. Diabetologia 67 (8) (2024)
Sofia Sterner Isaksson, Henrik Imberg, Irl B Hirsch, Erik Schwarcz, Jarl Hellman, Magnus Olof Wijkman, Jan Bolinder, Thomas Nyström, Helene Holmer, Sara Hallström, Arndís Finna Ólafsdóttir, Sofia Pekkari, William Polonsky, Marcus Lind
Discordance between mean glucose and time in range in relation to HbA 1c in individuals with type 1 diabetes: results from the GOLD and SILVER trials. Diabetologia (2024)
Thomas Nyström, Emilie Toresson Grip, Joel Gunnarsson, Paula Casajust, Kristina Karlsdotter, Josefin Skogsberg, Anastasia Ustyugova, null null
Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase-4 inhibitors: Real world evidence from the Nordic EMPRISE study. Diabetes, obesity & metabolism (2022)
Thomas Nyström, Erik Schwarz, Sofia Dahlqvist, Magnus Wijkman, Magnus Ekelund, Helen Holmer, Jan Bolinder, Jarl Hellman, Henrik Imberg, Irl B Hirsch, Marcus Lind
Evaluation of Effects of Continuous Glucose Monitoring on Physical Activity Habits and Blood Lipid Levels in Persons With Type 1 Diabetes Managed With MDI: An Analysis Based on the GOLD Randomized Trial (GOLD 8). Journal of diabetes science and technology (2022)
Göran Bratt, Johanna Brännström, Catharina Missalidis, Thomas Nyström
Development of type 2 diabetes and insulin resistance in people with HIV infection: Prevalence, incidence and associated factors. PloS one 16 (6) (2021)
Robin Kristófi, Johan Bodegard, Anna Norhammar, Marcus Thuresson, David Nathanson, Thomas Nyström, Kåre Inge Birkeland, Jan W Eriksson
Cardiovascular and Renal Disease Burden in Type 1 Compared With Type 2 Diabetes: A Two-Country Nationwide Observational Study. Diabetes care 44 (5) (2021)
B Rathsman, J Haas, M Persson, J Ludvigsson, A-M Svensson, M Lind, M Andersson Franko, Thomas Nyström
LDL cholesterol level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes mellitus: A nationwide cohort study. Journal of internal medicine 289 (6) (2020)
Thomas Nyström, Irene Santos-Pardo, Xin Fang, Dhanisha Jayesh Trivedi, Fredric Hedberg, Johan Jendle
Heart rate variability in type 2 diabetic subjects randomized to liraglutide or glimepiride treatment, both in combination with metformin: A randomized, open, parallel-group study. Endocrinology, diabetes & metabolism 2 (2) (2019)
Alexander Zabala, Vladimer Darsalia, Martin J Holzmann, Stefan Franzén, Ann-Marie Svensson, Björn Eliasson, Cesare Patrone, Thomas Nyström, Magnus Jonsson
Risk of first stroke in people with type 2 diabetes and its relation to glycaemic control: A nationwide observational study. Diabetes, obesity & metabolism 22 (2) (2019)
Anna Norhammar, Johan Bodegard, Thomas Nyström, Marcus Thuresson, S David Nathanson, Jan W Eriksson
Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study. Diabetes, obesity & metabolism 21 (5) (2019)
Thomas Nyström, Johan Bodegard, Thomas Nyström, Marcus Thuresson, Anna Norhammar, Jan W Eriksson
Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10. Diabetes care 41 (6) (2018)